Syngene International Limited (SYNGENE.NS)
INR 627.95
(-0.96%)
INR 627.95
(-0.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.93 Billion INR | -14.42% |
| 2022 | 22.13 Billion INR | -2.35% |
| 2021 | 22.66 Billion INR | 9.91% |
| 2020 | 20.61 Billion INR | 3.76% |
| 2019 | 19.87 Billion INR | 14.52% |
| 2018 | 17.35 Billion INR | 18.15% |
| 2017 | 14.68 Billion INR | 7.93% |
| 2016 | 13.6 Billion INR | 1.8% |
| 2015 | 13.36 Billion INR | 131.82% |
| 2014 | 5.76 Billion INR | 8.47% |
| 2013 | 5.31 Billion INR | 158.56% |
| 2012 | 2.05 Billion INR | -29.05% |
| 2011 | 2.89 Billion INR | 2.26% |
| 2010 | 2.83 Billion INR | -11.02% |
| 2009 | 3.18 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 17.42 Billion INR | -8.02% |
| 2024 Q2 | 17.4 Billion INR | -0.09% |
| 2023 Q4 | 18.93 Billion INR | 12.22% |
| 2023 Q1 | 22.16 Billion INR | 0.16% |
| 2023 Q2 | 19.55 Billion INR | -11.79% |
| 2023 Q3 | 16.87 Billion INR | -13.69% |
| 2023 FY | 18.93 Billion INR | -14.42% |
| 2022 Q3 | 21.09 Billion INR | 0.09% |
| 2022 Q4 | 22.13 Billion INR | 4.92% |
| 2022 FY | 22.13 Billion INR | -2.35% |
| 2022 Q1 | 21.19 Billion INR | -6.49% |
| 2022 Q2 | 21.07 Billion INR | -0.57% |
| 2021 FY | 22.66 Billion INR | 9.91% |
| 2021 Q2 | 18.49 Billion INR | -11.3% |
| 2021 Q4 | 22.66 Billion INR | 27.39% |
| 2021 Q3 | 17.79 Billion INR | -3.82% |
| 2021 Q1 | 20.85 Billion INR | 1.13% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 20.61 Billion INR | 3.76% |
| 2020 Q2 | 20.24 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 20.61 Billion INR | 0.0% |
| 2019 Q4 | 19.87 Billion INR | 0.0% |
| 2019 FY | 19.87 Billion INR | 14.52% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 18.65 Billion INR | 0.0% |
| 2018 FY | 17.35 Billion INR | 18.15% |
| 2018 Q2 | 17.17 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 17.35 Billion INR | 0.0% |
| 2017 Q4 | 14.68 Billion INR | 23.41% |
| 2017 Q2 | 12.28 Billion INR | 0.0% |
| 2017 FY | 14.68 Billion INR | 7.93% |
| 2017 Q3 | 11.9 Billion INR | -3.13% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 13.4 Billion INR | 0.0% |
| 2016 FY | 13.6 Billion INR | 1.8% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 13.6 Billion INR | 0.0% |
| 2015 FY | 13.36 Billion INR | 131.82% |
| 2015 Q3 | 4.78 Billion INR | -8.39% |
| 2015 Q2 | 5.21 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 13.36 Billion INR | 179.64% |
| 2014 Q4 | 5.76 Billion INR | 23.52% |
| 2014 FY | 5.76 Billion INR | 8.47% |
| 2014 Q1 | - INR | 0.0% |
| 2014 Q3 | 4.66 Billion INR | 0.0% |
| 2013 FY | 5.31 Billion INR | 158.56% |
| 2012 FY | 2.05 Billion INR | -29.05% |
| 2011 FY | 2.89 Billion INR | 2.26% |
| 2010 FY | 2.83 Billion INR | -11.02% |
| 2009 FY | 3.18 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biocon Limited | 307.95 Billion INR | 93.85% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | -786.562% |
| Concord Biotech Limited | 1.74 Billion INR | -988.054% |
| Dishman Carbogen Amcis Limited | 39.53 Billion INR | 52.1% |
| Jubilant Ingrevia Limited | 19.94 Billion INR | 5.04% |
| Lyka Labs Limited | 884.58 Million INR | -2040.999% |
| Panacea Biotec Limited | 4.02 Billion INR | -371.096% |
| Piramal Pharma Limited | 74 Billion INR | 74.408% |
| SMS Lifesciences India Limited | 1.96 Billion INR | -861.943% |
| Supriya Lifescience Limited | 1.05 Billion INR | -1688.892% |
| TAKE Solutions Limited | 969.78 Million INR | -1852.917% |
| Zota Health Care Limited | 1.38 Billion INR | -1268.901% |